These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26272586)

  • 1. Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects.
    Lau YY; Gu W; Lin T; Song D; Yu R; Scott JW
    J Clin Pharmacol; 2016 May; 56(5):559-66. PubMed ID: 26272586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Cho BC; Kim DW; Bearz A; Laurie SA; McKeage M; Borra G; Park K; Kim SW; Ghosn M; Ardizzoni A; Maiello E; Greystoke A; Yu R; Osborne K; Gu W; Scott JW; Passos VQ; Lau YY; Wrona A
    J Thorac Oncol; 2017 Sep; 12(9):1357-1367. PubMed ID: 28729021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: A clinical perspective.
    Otoukesh S; Sanchez T; Mirshahidi S; Wallace D; Mirshahidi H
    Cancer Treat Res Commun; 2019; 20():100149. PubMed ID: 31075537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase.
    Hong Y; Passos VQ; Huang PH; Lau YY
    J Clin Pharmacol; 2017 May; 57(5):652-662. PubMed ID: 27922734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors.
    Hurtado FK; de Braud F; De Castro Carpeño J; de Miguel Luken MJ; Wang D; Scott J; Lau YY; McCulloch T; Mau-Sorensen M
    Cancer Chemother Pharmacol; 2021 Apr; 87(4):475-486. PubMed ID: 33394101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceritinib for the treatment of non-small cell lung cancer.
    Landi L; Cappuzzo F
    Drugs Today (Barc); 2014 Jul; 50(7):465-73. PubMed ID: 25101329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy Subjects.
    Qian H; Fan S; Li K; Sai Y; Su W; Chen Q; Liu Y; Li T; Wang W; Jia J; Yu C; Liu Y
    Clin Ther; 2019 Aug; 41(8):1537-1544. PubMed ID: 31272709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.
    Cho BC; Obermannova R; Bearz A; McKeage M; Kim DW; Batra U; Borra G; Orlov S; Kim SW; Geater SL; Postmus PE; Laurie SA; Park K; Yang CT; Ardizzoni A; Bettini AC; de Castro G; Kiertsman F; Chen Z; Lau YY; Viraswami-Appanna K; Passos VQ; Dziadziuszko R
    J Thorac Oncol; 2019 Jul; 14(7):1255-1265. PubMed ID: 30851442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer.
    Kang CH; Kim EY; Kim HR; Lee CO; Lee HK; Jeong HG; Choi SU; Yun CS; Hwang JY; Lee JY; Son YH; Ahn S; Lee BH; Jung H; Park CH
    Cancer Lett; 2016 May; 374(2):272-8. PubMed ID: 26923554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
    Xu H; O'Gorman M; Boutros T; Brega N; Kantaridis C; Tan W; Bello A
    J Clin Pharmacol; 2015 Jan; 55(1):104-13. PubMed ID: 24990113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
    Ribas A; Zhang W; Chang I; Shirai K; Ernstoff MS; Daud A; Cowey CL; Daniels G; Seja E; O'Laco E; Glaspy JA; Chmielowski B; Hill T; Joe AK; Grippo JF
    J Clin Pharmacol; 2014 Apr; 54(4):368-74. PubMed ID: 24374975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of food and different meal types on the pharmacokinetics of rilpivirine.
    Crauwels HM; van Heeswijk RP; Buelens A; Stevens M; Boven K; Hoetelmans RM
    J Clin Pharmacol; 2013 Aug; 53(8):834-40. PubMed ID: 23720136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
    Fountzilas C; Adjei A; Opyrchal M; Evans R; Ghasemi M; Attwood K; Groman A; Bshara W; Goey A; Wilton J; Ma WW; Iyer R
    Int J Cancer; 2021 Dec; 149(12):2063-2074. PubMed ID: 34319586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
    Vansteenkiste JF
    Future Oncol; 2014 Oct; 10(12):1925-39. PubMed ID: 24856155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Venkatakrishnan K; Sonnichsen D; Kerstein D; Dorer DJ; Narasimhan N
    Clin Pharmacol Drug Dev; 2019 Aug; 8(6):734-741. PubMed ID: 30570839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products.
    Zhang S; Jin S; Griffin C; Feng Z; Lin J; Baratta M; Brake R; Venkatakrishnan K; Gupta N
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1028-1043. PubMed ID: 34118178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
    Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
    Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
    Landi L; Cappuzzo F
    Expert Rev Clin Pharmacol; 2016; 9(2):203-14. PubMed ID: 26582431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.